Being able to monitor drug concentration in the blood of a patient is an important aspect of any pharmaceutical treatment. However, this requires equipment and facilities that are often missing from field healthcare in developing countries, but also inhibits the quality of life for patients elsewhere. EPFL scientists, working through their startup LUCENTIX, have now developed an antibody-linked biosensor that can track drug concentration in the blood by changing its color. The biosensor is incorporated into a full system that can be used in the field or by patients at home. The science behind it is published in Angewandte Chemie.
The lab of Kai Johnsson at EPFL is known for developing biosensors, and the research gave birth to the startup LUCENTIX, which has developed a biosensor that allows patients to easily measure drug concentrations in their system without need for complex lab systems.
The biosensor is a molecule made up of three components: First, a protein that can bind the drug to be monitored. Second, the light-producing enzyme luciferase. And third, a "tagging" molecule called SNAP-tag, which carries a fluorescent ligand that the protein (the first component) recognizes and binds when no drug is present. This causes a reaction between the luciferase and the fluorescent molecule called "bioluminescent resonance energy transfer" (BRET), which produces a red light.
The recent innovation, carried out by postdoc Lin Xue, involves replacing the binding protein of the biosensor with part of an antibody that has been developed against the target drug. When the biosensor detects and binds the drug in the patient's blood or saliva, the antibody "prefers" to bind this rather than the SNAP-tag's fluorescent ligand. As the ligand is displaced, the BRET reaction is progressively disrupted, and now emits a blue light.
Antibodies are naturally able to identify and bind foreign molecules, turning our immune systems against potential infections. In addition, generating antibodies that can specifically identify small molecules like drugs is a routine procedure. This means that the monitoring system can be adapted to virtually an unlimited number of molecules, while patients can carry out the monitoring themselves at home and receive laboratory-level quality information. Current lab methods for doing this are complex and expensive, and reduce the quality of life for patients who have to often be confined within or close to hospitals.
Replacing the binding protein with an antibody establishes a general pipeline for the generation of biosensors that can identify a synthetic drug in a patient's blood sample. As proof-of-principle, the EPFL scientists successfully tested the new biosensors against three drugs - methotrexate, theophylline, and quinine - in the lab. The next step will be to optimize the biosensor's sensitivity so that it can accurately detect the nanomolar or even lower concentrations of drugs/biomolecules in clinical samples.
This work was funded by the Swiss National Science Foundation, the NCCR Chemical Biology, and EPFL. It also received contributions from EPFL's Protein Expression Core Facility.
Lin Xue, Qiuliyang Yu, Rudolf Griss, Alberto Schena, Kai Johnsson. Bioluminescent antibodies for point-of-care diagnostics. Angewandte Chemie 16 May 2017. DOI: 10.1002/anie.201702403
Angewandte Chemie International Edition